MaaT Pharma says EU drug panel maintains negative opinion on Xervyteg conditional approval
EMA’s CHMP upheld a negative opinion on conditional approval for Xervyteg in refractory gastrointestinal acute graft-versus-host disease. Regulators cited insufficient benefit-risk evidence from the single-arm dataset, keeping EU authorization at risk pending the Commission’s decision. Development focus shifts to the P